Published: October 17, 2023 at 6:21 pm ET
By Sabela Ojea
Impact Biomedical has filed for an initial public offering, according to a filing with the Securities and Exchange Commission.
The natural and plant-based technology provider said in Tuesday’s filing that it plans to list its shares on the New York Stock Exchange.
The…
By Sabela Ojea
Impact Biomedical has filed for an initial public offering, according to a filing with the Securities and Exchange Commission.
The natural and plant-based technology provider said in Tuesday’s filing that it plans to list its shares on the New York Stock Exchange.
The company did not disclose the number of shares being offered, the estimated share price or the ticker symbol.
In 2022, the company reported a net loss of $7.3 million, compared to a loss of $1.8 million in the same period last year. No revenue was reported.
Impact Biomedical said it expects to use approximately 40% of the net proceeds from the IPO for research and development, 10% for acquisitions and the remaining proceeds for capital purposes.
Write to Sabela Ojea at [email protected]
Comments are closed.